Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Haematologica|September 23, 2021
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
JCI Insight|January 5, 2021
Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometryLuciano Galdieri, Arijita Jash, Olga Malkova, et al.
Cell Communication and Signaling : CCS|December 16, 2025
A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignanciesFan He, Shuyang Lin, Bei Gao, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 11, 2026
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, et al.
JCI Insight|August 10, 2018
Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometryAllison A Throm, Halima Moncrieffe, Amir B Orandi, et al.
Cancer Immunology Research|June 26, 2025
SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid NeoplasmsMelinda A Biernacki, Jessica Lok, Kimberly A Foster, et al.
Leukemia|July 22, 2022
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben Mesa, Claire Harrison, Stephen T Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FBrady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Pageof 10